Mounjaro 2.5 mg (tirzepatide) is an injectable once weekly solution designed to help adults with type 2 diabetes achieve better blood sugar control. By activating both GIP and GLP 1 receptors, it stimulates insulin release when blood sugar is high, reduces liver glucagon production, Mounjaro 2.5mg/dose KwikPen Solution for Injection in Pre-filled Pen  slows gastric emptying, and increases fullness, all contributing to more stable glucose levels and reduced post meal spikes.The initial 2.5 mg dose is for treatment initiation, and ongoing use with diet and exercise supports improved glycemic control.With its once weekly injection schedule and dual action mechanism, Mounjaro offers an effective and convenient solution for long term diabetes management and metabolic health.